NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Ma
Post# of 110
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company today announced that its management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1×1 investor meetings. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer